{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'Each AE is to be evaluated for duration, severity, seriousness, and causal relationship to the', 'investigational drug. For all AEs, the Investigator must pursue and obtain information', 'adequate both to determine the outcome of the AE and to assess whether it meets the criteria', 'for classification as an SAE. The Investigator is required to assess causality as described', 'below.', 'Severity', 'The severity of AEs will be characterized according to the CTCAE grades and definitions', 'summarized in Table 4.', 'Table 4', 'CTCAE Grades and Corresponding AE Severity', 'CTCAE Grade', 'Corresponding AE Severity', 'Grade 1', 'Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only;', 'intervention not indicated', 'Grade 2', 'Moderate; minimal, local, or noninvasive intervention indicated; limiting', 'age-appropriate instrumental ADL', 'Grade 3', 'Severe or medically significant but not immediately life-threatening; hospitalization or', 'prolongation of hospitalization indicated; disabling; limiting self-care ADL', 'Grade 4', 'Life-threatening consequences; urgent intervention indicated', 'Grade 5', 'Death related to AE', 'Abbreviations: ADL = activities of daily living; AE = adverse event; CTCAE = Common Terminology Criteria', 'for Adverse Events.', 'Causality Assessment', 'The Investigator is responsible for making an assessment of the causal relationship between', 'the study treatment and the AE. Investigators should use their knowledge of the subject, the', 'circumstances surrounding the event, and an evaluation of any potential alternative causes to', 'determine whether or not an AE is considered to be related to the study treatment. The', 'causal relationship between the study treatment and the AE must be characterized as', '\"related\" or \"not related\". The following guidance should be taken into consideration:', 'Temporal relationship of event onset to the initiation of the study treatment.', 'Course of the event, considering especially the effects of dose reduction,', 'discontinuation of the study treatment, or reintroduction of the study treatment.', 'Known association of the event with the study treatment, or with similar treatments.', 'Known association of the event with the disease under study.', 'Amendment 2: 06 March 2019', '98', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'Presence of risk factors in the subject or use of concomitant medications known to', 'increase the occurrence of the event.', 'Presence of non-treatment-related factors that are known to be associated with the', 'occurrence of the event.', 'The Investigator should report the relatedness of each event based on the most likely causal', 'relationship, and the study site staff is responsible for obtaining any missing information.', '7.4.1.1', 'Eliciting Adverse Event Information', 'A consistent methodology of non-directive questioning should be adopted for eliciting AE', 'information at all subject evaluation time points. Examples of nondirective questions from', 'the Investigator to the subject include the following:', '\"How have you felt since your last clinic visit?\"', '\"Have you had any new or changed health problems since you were last here?\\'', '7.4.2', 'Serious Adverse Events', 'An SAE experience or reaction is any untoward medical occurrence (whether considered to', 'be related to the study treatment or not) that at any dose:', 'Results in death', 'Is life-threatening (the subject is at a risk of death at the time of the event; it does not', 'refer to an event that hypothetically might have caused death if it were more severe)', 'Requires subject hospitalization or prolongation of existing hospitalization', 'Results in persistent or significant disability/incapacity', 'Is a congenital abnormality/birth defect', 'Other medically significant events, which do not meet any of the criteria above, but', 'may jeopardize the subject and may require medical or surgical intervention to prevent', '1 of the other serious outcomes listed in the definition above.', '- Examples of such events are blood dyscrasias (e.g., neutropenia or anemia requiring', 'blood transfusion, etc) or convulsions that do not result in hospitalization.', '- Confirmed cases of active TB should be recorded and reported as SAEs.', '-', 'Potential hepatotoxicity events that fulfill any of the following criteria should be', 'recorded and reported as SAEs:', 'Amendment 2: 06 March 2019', '99', 'Confidential']\n\n###\n\n", "completion": "END"}